A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 in Active Plaque Psoriasis
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2015
At a glance
- Drugs Dalazatide (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Proof of concept
- Sponsors Kineta
- 09 Jun 2015 As per a Kineta media release, results from this trial will be presented at the Biotechnology Industry Organization (BIO) Annual Meeting in Philadelphia.
- 05 May 2015 Results were published in a Kineta media release.
- 05 May 2015 According to a Kineta media release, results from biomarker analysis of this study are expected to be available in the second quarter of 2015.